Expedition Growth Capital led the Series A round, which will support global expansion and product development.
"We founded ThreatSpike having witnessed first-hand that achieving high quality cybersecurity protection is far too complex and costly. In a market full of three-letter acronym products and aggressive upselling, we take a different approach which puts customer security at the core. We are proud to combine world-class technology and expert support into one transparent, flexible solution that delivers true protection without the complexity or hidden costs. With this investment from Expedition, we have gained an aligned partner with deep expertise and resources to support our continued growth journey."
The Dublin-based HR tech startup secured the capital from Eurazeo alongside existing backers to grow its team and carrier network.
"As a founder and GM, I experienced how managing benefits through email, between brokers and insurance companies, was completely disconnected and alien from everything else in the business."
The Cardiff-based space tech startup has secured the largest Series A round in the UK sector to advance its in-orbit manufacturing missions.
"This funding marks a significant milestone-not just for Space Forge, but for the entire space economy. With the backing of our investors, we're accelerating our mission to make space a practical and accessible platform for industrial-scale manufacturing. Our upcoming launches will prove that the future of materials innovation lies beyond Earth, helping us build a more secure, sustainable, and technologically advanced world."
Nodenza Venture Partners has led a Series A round to fund manufacturing expansion and US growth.
"Our mission is to make advanced surgical planning tools accessible and scalable across the US healthcare system. This investment allows us to accelerate our plan to enable every orthopaedic surgeon in the US to have easy access to personalised surgical devices within surgically meaningful timelines. We’re excited to build on the momentum we’ve already seen with leading clinicians."
